- Debate over Elon Musk’s “idiot index” method: participants questioned whether raw-material cost alone is a valid metric, noting that energy and processing overhead are missing and that the index’s real utility may be exposing supplier price inflation.  
- Mitochondria-injection therapy was highlighted via the startup Mitrix Bio (https://www.mitrix.bio/), framed as a potential longevity or performance intervention.  
- Rapid Liquid Printing technology (https://www.rapidliquidprint.com/) was shared as an open additive-manufacturing approach for soft, large, or complex structures.  
- A lengthy discussion addressed how an independent, cash-strapped biohacker can gain scientific credibility for a new molecular-biology method without traditional peer review; consensus favored self-publishing white-papers, posting to arXiv, engaging DIYbio communities, and commercializing a kit to let third-party validation speak for itself.  
- Participants argued that mainstream scientific institutions suffer a “credibility crisis,” making alternative dissemination (blogs, Twitter, direct sales) often more effective than journal publication for adoption.